![ORCID 0000-0002-0169-998X](/images/orcid_16x16.gif)
![ORCID 0000-0002-3813-8772](/images/orcid_16x16.gif)
![ORCID 0000-0001-9442-7141](/images/orcid_16x16.gif)
![ORCID 0000-0002-2560-4068](/images/orcid_16x16.gif)
![ORCID 0000-0001-5243-8985](/images/orcid_16x16.gif)
![ORCID 0000-0001-9915-4429](/images/orcid_16x16.gif)
![ORCID 0000-0001-8325-250X](/images/orcid_16x16.gif)
![ORCID 0000-0002-6158-5087](/images/orcid_16x16.gif)
Dokumentenart: | Artikel | ||||
---|---|---|---|---|---|
Titel eines Journals oder einer Zeitschrift: | American Heart Journal | ||||
Verlag: | MOSBY-ELSEVIER | ||||
Ort der Veröffentlichung: | NEW YORK | ||||
Band: | 234 | ||||
Seitenbereich: | S. 1-11 | ||||
Datum: | 2021 | ||||
Institutionen: | Medizin > Lehrstuhl für Innere Medizin II | ||||
Identifikationsnummer: |
| ||||
Stichwörter / Keywords: | MEMBRANE-OXYGENATION; LEFT-VENTRICLE; MANAGEMENT; THERAPY; | ||||
Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
Status: | Veröffentlicht | ||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||
An der Universität Regensburg entstanden: | Ja | ||||
Dokumenten-ID: | 56758 |
Zusammenfassung
Background In acute myocardial infarction complicated by cardiogenic shock the use of mechanical circulatory support devices remains controversial and data from randomized clinical trials are very limited. Extracorporeal life support (ECLS) venoarterial extracorporeal membrane oxygenation provides the strongest hemodynamic support in addition to oxygenation. However, despite increasing use it has ...
![plus plus](/style/images/plus.png)
Zusammenfassung
Background In acute myocardial infarction complicated by cardiogenic shock the use of mechanical circulatory support devices remains controversial and data from randomized clinical trials are very limited. Extracorporeal life support (ECLS) venoarterial extracorporeal membrane oxygenation provides the strongest hemodynamic support in addition to oxygenation. However, despite increasing use it has not yet been properly investigated in randomized trials. Therefore, a prospective randomized adequately powered clinical trial is warranted. Study Design The ECLS-SHOCK trial is a 420-patient controlled, international, multicenter, randomized, open-label trial. It is designed to compare whether treatment with ECLS in addition to early revascularization with percutaneous coronary intervention or alternatively coronary artery bypass grafting and optimal medical treatment is beneficial in comparison to no-ECLS in patients with severe infarct-related cardiogenic shock. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary efficacy endpoint of ECLS-SHOCK is 30-day mortality. Secondary outcome measures such as hemodynamic, laboratory, and clinical parameters will serve as surrogate endpoints for prognosis. Furthermore, a longer follow-up at 6 and 12 months will be performed including quality of life assessment. Safety endpoints include peripheral ischemic vascular complications, bleeding and stroke. Conclusions The ECLS-SHOCK trial will address essential questions of efficacy and safety of ECLS in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock.
Metadaten zuletzt geändert: 29 Feb 2024 12:37